Thomas John Dietz - Net Worth and Insider Trading
Thomas John Dietz Net Worth
The estimated net worth of Thomas John Dietz is at least $16,402 dollars as of 2024-05-04. Thomas John Dietz is the Director of Paratek Pharmaceuticals Inc and owns about 4,500 shares of Paratek Pharmaceuticals Inc (PRTK) stock worth over $10,035. Thomas John Dietz is also the Director of Eiger BioPharmaceuticals Inc and owns about 2,367 shares of Eiger BioPharmaceuticals Inc (EIGRQ) stock worth over $6,367. Details can be seen in Thomas John Dietz's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Thomas John Dietz has not made any transactions after 2023-01-23 and currently still holds the listed stock(s).
Transaction Summary of Thomas John Dietz
Thomas John Dietz Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Thomas John Dietz owns 3 companies in total, including Leap Therapeutics Inc (LPTX) , Eiger BioPharmaceuticals Inc (EIGRQ) , and Paratek Pharmaceuticals Inc (PRTK) .
Click here to see the complete history of Thomas John Dietz’s form 4 insider trades.
Insider Ownership Summary of Thomas John Dietz
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| LPTX | Leap Therapeutics Inc | 2017-01-20 | director |
| EIGRQ | Eiger BioPharmaceuticals Inc | 2023-01-23 | director |
| PRTK | Paratek Pharmaceuticals Inc | 2023-09-21 | director |
Thomas John Dietz Latest Holdings Summary
Thomas John Dietz currently owns a total of 2 stocks. Among these stocks, Thomas John Dietz owns 4,500 shares of Paratek Pharmaceuticals Inc (PRTK) as of February 15, 2019, with a value of $10,035 and a weighting of 61.18%. Thomas John Dietz also owns 2,367 shares of Eiger BioPharmaceuticals Inc (EIGRQ) as of January 23, 2023, with a value of $6,367 and a weighting of 38.82%.
Latest Holdings of Thomas John Dietz
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| PRTK | Paratek Pharmaceuticals Inc | 2019-02-15 | 4,500 | 2.23 | 10,035 |
| EIGRQ | Eiger BioPharmaceuticals Inc | 2023-01-23 | 2,367 | 2.69 | 6,367 |
Holding Weightings of Thomas John Dietz
Thomas John Dietz Form 4 Trading Tracker
According to the SEC Form 4 filings, Thomas John Dietz has made a total of 0 transactions in Paratek Pharmaceuticals Inc (PRTK) over the past 5 years. The most-recent trade in Paratek Pharmaceuticals Inc is the sale of 3,000 shares on February 15, 2019, which brought Thomas John Dietz around $21,420.
According to the SEC Form 4 filings, Thomas John Dietz has made a total of 5 transactions in Eiger BioPharmaceuticals Inc (EIGRQ) over the past 5 years, including 4 buys and 1 sells. The most-recent trade in Eiger BioPharmaceuticals Inc is the acquisition of 1,667 shares on January 23, 2023, which cost Thomas John Dietz around $71,500.
Insider Trading History of Thomas John Dietz
- 1
Thomas John Dietz Trading Performance
GuruFocus tracks the stock performance after each of Thomas John Dietz's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Thomas John Dietz is 11.8%. GuruFocus also compares Thomas John Dietz's trading performance to market benchmark return within the same time period. The performance of stocks bought by Thomas John Dietz within 3 months outperforms 3 times out of 8 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Thomas John Dietz's insider trading performs compared to the benchmark.
Performance of Thomas John Dietz
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 15.39 | | | | | |
| Relative Return to S&P 500(%) | 13.02 | | | | | |
Thomas John Dietz Ownership Network
Thomas John Dietz Owned Company Details
What does Leap Therapeutics Inc do?
Who are the key executives at Leap Therapeutics Inc?
Thomas John Dietz is the director of Leap Therapeutics Inc. Other key executives at Leap Therapeutics Inc include Chief Scientific Officer Jason Baum , 10 percent owner Beigene, Ltd. , and VP & Head of Reg Affairs/Qual Christine Granfield .
Leap Therapeutics Inc (LPTX) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Leap Therapeutics Inc (LPTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Leap Therapeutics Inc (LPTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Leap Therapeutics Inc (LPTX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Leap Therapeutics Inc Insider Transactions
Thomas John Dietz Mailing Address
Above is the net worth, insider trading, and ownership report for Thomas John Dietz. You might contact Thomas John Dietz via mailing address: C/o Transcept Pharmaceutical, Inc., 1003 W. Cutting Blvd, Ste 110, Pt. Richmond Ca 94804.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
